Effects of Antiarrhythmics on Cardiac Phenotype and Redox Balance in Spontaneously Hypertensive Rats
Authors:
- Stefan M. SimovićStefan M. Simović
- Ivan M. SrejovićISIvan M. Srejović
- Goran T. DavidovićGDGoran T. Davidović
- Maja D. MurićMMMaja D. Murić
- Slobodanka L. MitrovićSMSlobodanka L. Mitrović
- Marko P. RavićMRMarko P. Ravić
- Marijana M. AndjićMAMarijana M. Andjić
- Marina R. NikolićMNMarina R. Nikolić
- Katarina G. MihajlovićKMKatarina G. Mihajlović
- Nevena D. LazarevićNLNevena D. Lazarević
- Sergey B. BolevichSBSergey B. Bolevich
- Aleksandra S. OrlovaAOAleksandra S. Orlova
Open Access
- 21 July 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6490
Abstract
Arterial hypertension is a well-known risk factor for cardiac arrhythmias, while certain antihypertensive agents may also create conditions for arrhythmia occurrence. The aim of this study was to evaluate the effects of selected class III antiarrhythmic drugs on cardiac function and structure, as well as on oxidative stress status, in spontaneously hypertensive rats (SHRs). Male SHRs were treated for 4 weeks with dronedarone, amiodarone, or dofetilide. Cardiac function was assessed in vivo by echocardiography and ex vivo using the Langendorff model. Oxidative stress markers, myocardial morphology, and HSP70 and SERCA2 expression were analyzed. All drugs partially improved cardiac function in vivo, with dronedarone exerting the strongest antihypertensive effect. Ex vivo, dofetilide enhanced contractility and dronedarone reduced cardiac performance, whereas amiodarone showed intermediate effects. Oxidative stress was differentially modulated, with dofetilide and amiodarone improving antioxidant defenses, while dronedarone showed heterogeneous effects. Histologically, dofetilide preserved myocardial architecture most effectively, while amiodarone and dronedarone partially attenuated hypertensive remodeling. Treatments decreased HSP70 expression, while increasing SERCA2 expression, particularly in the dofetilide group. Class III antiarrhythmic drugs differentially affect cardiac function, redox balance, calcium handling, and myocardial remodeling in hypertension, which may contribute to their distinct antiarrhythmic and cardioprotective properties.Keywords
Funding Information
- Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu (JP 13/19)
- Ministry of Science, Technical Development, and Innovation of the Republic of Serbia (451-03-34/2026-03/200111)
This publication has 48 references indexed in Scilit:
- The modernized classification of cardiac antiarrhythmic drugs: Its application to clinical practiceHeart Rhythm, 2025
- Immortelle essential oil-based ointment improves wound healing in a diabetic rat modelBiomedicine & Pharmacotherapy, 2022
- Relevance of mitochondrial oxidative stress to arrhythmias: Innovative concepts to target treatmentsPharmacological Research, 2022
- In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic DrugsCardiovascular Toxicology, 2017
- Mitochondrial dysfunction in heart failureHeart Failure Reviews, 2012
- Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administrationFree Radical Biology and Medicine, 2011
- Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive ratsBasic Research in Cardiology, 2008
- Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heartEuropean Journal of Pharmacology, 2004
- Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heartEuropean Journal of Pharmacology, 2002
- Cellular electropharmacology of amiodaroneCardiovascular Research, 1997